Durham agtech startup Avalo secures $11M in funding
Avalo is a Duke agtech start-up based on technology developed by former postdoc Mariano Alvarez (Biology, Trinity) and Professor Cynthia Rudin (CS, Trinity).
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Finding the right fit: inventive Duke students get crash course in commercializing their technologies
Making customer calls and polishing pitches – Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp.
Lumotive Raises $45 Million to Expand Sales of Programmable Optical Semiconductors
Lumotive is a metamaterials start-up spun out of the labs of Professor David Smith and Associate Professor Maiken Mikkelsen (ECE, Pratt). Mikkelsen's former postdoc Gleb Akselrod is the founder and CTO.
Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies
DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).
Interdisciplinarity and impact shine at Duke Research and Innovation Summit 2025
The annual gathering of the Duke research community emphasized how innovators are making an impact through their research.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.